Furthermore, Ddx5 depletion has enhanced AML treatment outcomes by inducing cell cycle arrest, apoptosis, downregulation of glucose metabolism-related genes, and increasing ROS levels.39 This evidence concerns the gene DDX5 and acute myeloid leukemia.